Akcea Therapeutics names new EVP and CFO
19 May 2020 -

Akcea Therapeutics Inc (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals Inc, has named Michael D Price as its new executive vice president and chief financial officer, it was reported on Monday.

In the new role, Price will manage financial operations at the company including managing financial strategies and activities related to clinical and regulatory functions, commercial sales, marketing, manufacturing and supply chain.

Price has over 25 years of experience in the pharmaceutical industry. Prior to joining Akcea, he served as EVP and CFO and was elected to the company's board of directors of Novelion Therapeutics. He has also served as VP and CFO at Noven Pharmaceuticals Inc from 2007 to 2016. From 1992 to 2006, he has worked at Bentley Pharmaceuticals Inc serving as VP, CFO, treasurer and secretary. He was also a member of Bentley's board of directors for nine years.